Cargando...

Preclinical Efficacy of Cystatin C to Target the Oncogenic Activity of Transforming Growth Factor β in Breast Cancer,

We previously identified cystatin C (CystC) as a novel antagonist of transforming growth factor β (TGF-β) signaling in normal and malignant cells. However, whether the anti-TGF-β activities of CystC can be translated to preclinical animal models of breast cancer growth and metastasis remains unprove...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tian, Maozhen, Schiemann, William P
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press Inc. 2009
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2730134/
https://ncbi.nlm.nih.gov/pubmed/19701502
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!